Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
April 29, 2021 at 02:23 am
Share
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 959.099 million compared to CNY 181.155 million a year ago. Operating income was CNY 562.278 million compared to CNY 41.538 million a year ago. Net income was CNY 468.927 million compared to CNY 41.525 million a year ago. Basic earnings per share from continuing operations was CNY 6.98 compared to CNY 0.62 a year ago.
Wuhan Easy Diagnosis Biomedicine Co., Ltd. is a China-based company which is mainly engaged in research and development, manufacture and sales of Point of Care Testing (POCT) rapid diagnostic reagents and quick testing instruments. The Company's main products are POCT rapid diagnostic reagents, which can be divided into six categories: infectious diseases, cardiovascular and cerebrovascular diseases, kidney diseases, diabetes, gynecology and eugenics, and health checkups. The Company's main products are mainly used in domestic hospitals, health service centers, community clinics, medical examination centers and other medical institutions.
WUHAN EASY DIAGNOSIS BIOMEDICINE CO.,LTD. 
